Journal of Psychedelic Studies
December 2, 2023
Mark Haden, Birgitta Woods, Sarah A. Paschall
3 citations
A review of current and historical research and clinical reports finds that the relationship between psychedelics and schizophrenia is complex, with some evidence that psychedelics may benefit this population. Specifically, lower doses of psychedelics, mostly LSD, appear to have a potential beneficial impact on the negative symptoms of schizophrenia.
Journal of Psychedelic Studies
July 3, 2025
Mark Haden, Sarah A. Paschall, Birgitta Woods
2 citations
A review of 104 peer-reviewed articles finds that naturalistic use of psychedelics like psilocybin, LSD, MDMA, mescaline, and 5-MeO-DMT is associated with reductions in depression, anxiety, PTSD, substance use disorders, interpersonal violence, and suicidality, while enhancing emotional well-being, social connectedness, spirituality, nature relatedness, psychological flexibility, and physical health. Benefits appear across diverse populations, including those with trauma, addictions, chronic pain, older adults, and marginalized groups. Adverse effects are typically short-lived and linked to risk factors like youth, high doses, psychological vulnerability, and poor set and setting. The authors argue that prohibitionist policies are outdated and harmful, advocating for legalization, regulated access, and evidence-informed education grounded in harm reduction and Indigenous cultural models.